Revelation Biosciences, Inc. (REVBW) — SEC Filings
Revelation Biosciences, Inc. (REVBW) — 50 SEC filings. Latest: 8-K (Dec 3, 2025). Includes 29 8-K, 6 10-Q, 5 DEF 14A.
View Revelation Biosciences, Inc. on SEC EDGAR
Overview
Revelation Biosciences, Inc. (REVBW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Revelation Biosciences, Inc. filed an 8-K on December 3, 2025, reporting material modifications to security holder rights and submitting matters to a vote. The filing also includes other events and financial statements/exhibits. The company was formerly known as Petra Acquisition Inc. until April 23
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 8 bearish, 41 neutral. The dominant filing sentiment for Revelation Biosciences, Inc. is neutral.
Filing Type Overview
Revelation Biosciences, Inc. (REVBW) has filed 29 8-K, 5 DEF 14A, 6 10-Q, 3 S-1/A, 1 S-1, 2 10-K, 1 DEFA14A, 1 10-K/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of REVBW's 44 recent filings, 5 were flagged as high-risk, 20 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$6.4M |
| EPS | -$9.76 |
| Debt-to-Equity | 0.17 |
| Cash Position | $12.7M |
| Operating Margin | N/A |
| Total Assets | $12.9M |
| Total Debt | $1.9M |
Key Executives
- Chester S. Zygmont, III
- James Rolke
- Class C director
- J.P. Galda, Esq.
- Charles Phillips, Esq.
- J.P. Galda
- Charles Phillips
Industry Context
Revelation Biosciences operates in the biotechnology sector, a highly competitive and research-intensive industry. Success often hinges on the ability to advance drug candidates through clinical trials and secure regulatory approvals. Companies in this space frequently rely on capital raises and strategic partnerships to fund their operations and development pipelines.
Top Tags
corporate-action (8) · financials (8) · Biotechnology (7) · warrants (7) · filing (6) · 8-K (6) · material-agreement (5) · Proxy Statement (4) · Warrants (4) · 10-Q (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 20251203 | Date of the 8-K filing |
| Share issuance cap | 20% | Threshold under Nasdaq Rule 5635(d) that the warrant issuance may exceed |
| Shares of common stock outstanding | 5,924,137 | As of the October 29, 2025 record date |
| Shares required for quorum | 1,974,713 | One third of outstanding shares needed for the Special Meeting |
| Date of Class I Common Stock Warrants | September 11, 2025 | Date of the warrants subject to shareholder approval |
| Date of warrant inducement letter | September 10, 2025 | Precedes the Warrants and outlines the inducement terms |
| Date of Special Meeting | December 3, 2025 | When stockholders will vote on the proposals |
| Record Date | October 29, 2025 | Determines stockholders entitled to vote at the Special Meeting |
| Net Loss | $6.4M | for the nine months ended September 30, 2025, an improvement from $13.3M in 2024 |
| Cash and Cash Equivalents | $12.7M | as of September 30, 2025, up from $6.5M at December 31, 2024 |
| Accumulated Deficit | $46.9M | as of September 30, 2025, indicating significant historical losses |
| Net Cash from Financing Activities | $12.5M | for the nine months ended September 30, 2025, primarily from offerings and warrant exercises |
| Reverse Stock Split | 1-for-16 | effected on January 28, 2025 |
| Research and Development Expenses | $3.1M | for the nine months ended September 30, 2025, up from $2.9M in 2024 |
| General and Administrative Expenses | $3.4M | for the nine months ended September 30, 2025, up from $3.3M in 2024 |
Forward-Looking Statements
- {"claim":"The exercise of these warrants will lead to an increase in the total outstanding shares of Revelation Biosciences, Inc.","entity":"REVELATION BIOSCIENCES, INC.","targetDate":"N/A (upon warrant exercise)","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Revelation Biosciences, Inc. (REVBW)?
Revelation Biosciences, Inc. has 50 recent SEC filings from Jan 2024 to Dec 2025, including 29 8-K, 6 10-Q, 5 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of REVBW filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 8 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Revelation Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Revelation Biosciences, Inc. (REVBW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Revelation Biosciences, Inc.?
Key financial highlights from Revelation Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for REVBW?
The investment thesis for REVBW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Revelation Biosciences, Inc.?
Key executives identified across Revelation Biosciences, Inc.'s filings include Chester S. Zygmont, III, James Rolke, Class C director, J.P. Galda, Esq., Charles Phillips, Esq. and 2 others.
What are the main risk factors for Revelation Biosciences, Inc. stock?
Of REVBW's 44 assessed filings, 5 were flagged high-risk, 20 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Revelation Biosciences, Inc.?
Recent forward-looking statements from Revelation Biosciences, Inc. include guidance on {"claim":"The exercise of these warrants will lead to an increase in the total outstanding shares of Revelation Bioscien.